Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 2-Year Study To Evaluate The Effects Of GPI 1485 On [123I]b-CIT/SPECT Scanning And Clinical Efficacy In Symptomatic PD Patients Receiving Dopamine Agonist Therapy.
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2009
At a glance
- Drugs GM 1485 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors MGI GP
- 05 Nov 2008 Sponsor and affiliate changed from MGI Pharma to Eisai Medical Research, based on information from ClinicalTrials.gov.
- 14 Oct 2008 Checked against ClinicalTrials.gov record.
- 02 Nov 2006 Results have been reported.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History